Physician profile
Alan Colvin
NPI 1033879150
$1,726.65
in general payments reported to CMS, 2019-2025
21 companies · $799 in 2025
The $799 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $11.71 · 2023: $259 · 2024: $657 · 2025: $799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,714.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $326.68 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $227.52 | 2023-2025 | |
| Lilly USA, LLC | $171.89 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.69 | 2023-2025 | Jardiance |
| Astellas Pharma US INC | $110.51 | 2023-2025 | Veozah |
| Pfizer INC. | $102.60 | 2023-2025 | |
| Exact Sciences Corporation | $92.75 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $82.10 | 2024-2025 | Airsupra, Farxiga |
| Otsuka America Pharmaceutical, INC. | $61.83 | 2023-2025 | Rexulti |
| Amgen INC. | $58.99 | 2023-2025 | Repatha, Repatha |
| Dexcom, INC. | $50.52 | 2024-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $50.27 | 2024-2025 | Arexvy, Shingrix |
| Abiomed | $48.17 | 2024-2025 | Impella |
| Xeris Pharmaceuticals, INC. | $41.58 | 2023-2024 | Keveyis |
| Axsome Therapeutics, INC. | $39.44 | 2025 | Auvelity |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $28.24 | 2024 | |
| Sanofi Pasteur INC. | $25.52 | 2024 | |
| Sumitomo Pharma America, INC. | $25.24 | 2025 | Gemtesa |
| Hologic Sales and Service, LLC | $20.00 | 2025 | Thinprep 2000 Processor, Aptima |
| Merck Sharp & Dohme LLC | $15.69 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Sonex Health, INC. | $15.42 | 2025 | Sx-One Microknife |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Colvin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.